Indian Pharmaceutical companies, from Sun Pharma Ltd., to Lupin Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Gland Pharma Ltd., will be reacting on Wednesday, April 9, after US President Donald Trump said that he will be announcing major tariffs on the Pharma sector soon. Speaking at the Republican NRCC event, Trump said that major […]
Pharma Stocks Crash: Donald Trump says tariffs will be at ‘never seen before’ levels – CNBC TV18
Shares of Indian Pharma Companies, Aurobindo Pharma, IPCA Laboratories, Lupin and others fell up to 5% on Friday, April 4, after US President Donald Trump remarked about the upcoming tariffs on the sector. “Pharma tariffs are going to come in at levels you have never seen before. We are looking at pharmaceuticals as a separate […]
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment – CNBC TV18
Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab (marketed as Stelara). The randomised, double-blind, parallel-group, multi-centre study evaluated Yesintek in adult patients with moderate to severe chronic plaque psoriasis (PsO). The findings, which […]
Biocon Biologics partners with US non-profit co to make diabetes treatment cheaper for Americans – CNBC TV18
Biotechnology firm Biocon Ltd on Thursday (March 6) said its arm Biocon Biologics Ltd has entered into a strategic collaboration with Civica Inc, a not-for-profit pharmaceutical company, to enhance the accessibility and affordability of insulin aspart in the United States. Civica, founded in 2018, focuses on addressing life-saving drug shortages and reducing costs for essential […]
Stocks to Watch on March 7: RVNL, Brigade Enterprises, Kalpataru Projects, RITES and more – CNBC TV18
SUMMARY Stocks to watch, RVNL, Brigade Enterprises, Kalpataru Projects, RITES, Bajaj Finserv, Biocon and more, these are the stocks to watch for today. 1 / 6 RVNL | State-owned company said it has received a letter of acceptance from South Western Railway for an engineering, procurement, and construction (EPC) contract valued at ₹156.36 crore (including […]
Stocks to Watch on March 5: Biocon, Adani Wilmar, Ola Electric, Power Grid and more – CNBC TV18
1 / 14 Biocon | Biotechnology firm said its wholly-owned subsidiary, Biocon Pharma Ltd, has received final approvals from the US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs). Lenalidomide capsules, in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg strengths. Lenalidomide is a medication used […]
Trade Setup for March 5: How long will the Nifty resilience last amidst tariff uncertainties? – CNBC TV18
With the way the markets have behaved in the recent past, the Nifty bulls would gleefully take a day which turned out to be in the “not as bad as feared” category. The 22,000 level on the index was firmly under threat early Tuesday morning post the sharp sell-off on Wall Street post the imposition […]
Biocon gets FDA nod for cancer drugs lenalidomide and dasatinib – CNBC TV18
Biotechnology firm Biocon Ltd on Tuesday (March 4) said its wholly-owned subsidiary, Biocon Pharma Ltd, has received final approvals from the US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs). Lenalidomide capsules, in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg strengths. Lenalidomide is a medication […]
Biocon launches generic Liraglutide in the UK for diabetes, obesity treatment – CNBC TV18
Biopharmaceutical firm Biocon Ltd announced the launch of its Glucagon-like Peptide-1 (GLP-1) analog, Liraglutide, in the United Kingdom (U.K.). The drug is used for the treatment of diabetes and obesity. This launch follows the nod from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the first generics company to receive approval for […]
Stocks to Watch on February 25: Biocon, NTPC Green Energy, LIC, Texmaco Rail and more – CNBC TV18
1 / 8 Biocon | Biotechnology firm said its unit Biocon Biologics announced the US market availability of YESINTEK (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab). This makes YESINTEK one of the first biosimilar alternatives to enter the US market for the blockbuster immunology drug. YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, […]